Navigation Links
SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

SAN DIEGO, March 4 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) will announce financial results for the fourth quarter and full year 2007 on Wednesday, March 12, 2008. The announcement will be followed by a live conference call and webcast at 8:00 a.m. Pacific Time. Mike Grey, President and Chief Executive Officer, and Todd Myers, Chief Financial Officer, will host the conference call to discuss financial results and business highlights.

Interested participants and investors may access the teleconference call by dialing 800-573-4752 (U.S./Canada) or 617-224-4324 (international), participant code 20358556. A telephonic replay will be available for seven days following the call. Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international), participant code 55640708.

A live webcast will be available under the investor relations section of the Company's website at http://www.sgxpharma.com. Replays of the webcast will be available for 30 days following the event. Please connect to the Company's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About SGX Pharmaceuticals

SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The SGX oncology pipeline includes drug candidates from its FAST(TM) drug discovery platform, such as SGX523, a cMET kinase inhibitor currently in Phase 1 clinical studies, next generation BCR-ABL inhibitors being developed by SGX and in collaboration with Novartis, and JAK2 inhibitors. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.


'/>"/>
SOURCE SGX Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
2. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
7. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
8. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
9. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
10. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
11. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... the FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI Express, ... require FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits ...
(Date:12/8/2016)...  Anaconda BioMed S.L., a pre-clinical stage medical device ... neuro-thrombectomy system for the treatment of Acute Ischemic Stroke ... to join its Scientific Advisory Board (SAB). The SAB ... scientific and clinical experts to Anaconda BioMed S.L., as ... ® to its clinical phase. The SAB is ...
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics leader, ... uBiome is one of just six company finalists in the Health & Medicine ... uBiome, companies nominated as finalists in this year’s awards include Google, SpaceX, Oculus, ...
(Date:12/8/2016)... 2016 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... and commercializing products to treat rare diseases where there ... will be hosting an Investor Webcast Event Friday, December ... of innate defense regulators (IDRs) as a new drug ... and the recently announced and published Phase 2 clinical ...
Breaking Biology Technology:
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is ... analysis for Private Biobanks shows the highest Compounded Annual Growth ... region during the analysis period 2014-2020. ... CAGR of 9.95% followed by Europe ...
(Date:11/16/2016)... SANTA CLARA, Calif. , Nov. 16, 2016 /PRNewswire/ ... company enhancing user experience and security for consumer ... provider for the financial and retail industry, today ... more secure and convenient way to authenticate users ... now uses Sensory,s TrulySecure™ software which ...
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
Breaking Biology News(10 mins):